This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the genetics of breast and ovarian cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Clinical validity refers to the predictive value of a test for a given clinical outcome (e.g., the likelihood that cancer will develop in someone with a positive test). It is primarily determined by the sensitivity and specificity with which a test identifies people with a defined clinical condition within a given population. Sensitivity of a test refers to the proportion of people who test positive for a clinical condition among those who actually have the clinical condition; specificity refers...
This summary is reviewed regularly and updated as necessary by the PDQ Cancer Genetics Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
be discussed at a meeting,
be cited with text, or
replace or update an existing article that is already cited.
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
The lead reviewers for Genetics of Breast and Ovarian Cancer are:
Kathleen A. Calzone, PhD, RN, APNG, FAAN (National Cancer Institute)
Ilana Cass, MD (Cedars-Sinai Medical Center)
Mary B. Daly, MD, PhD (Fox Chase Cancer Center)
Susan Domchek, MD (University of Pennsylvania Cancer Center)
Donald W. Hadley, MS, CGC (National Human Genome Research Institute)
Jennifer Lynn Hay, PhD (Memorial Sloan-Kettering Cancer Center)
Karen H. Lu, MD (University of Texas, M.D. Anderson Cancer Center)
Suzanne M. O'Neill, MS, PhD, CGC (Northwestern University)
Tuya Pal, MD, FAAP, FABMG (H. Lee Moffitt Cancer Center & Research Institute)
Susan K. Peterson, PhD, MPH (University of Texas, M.D. Anderson Cancer Center)
Jeffery P. Struewing, MD (National Human Genome Research Institute)
Susan T. Vadaparampil, PhD, MPH (H. Lee Moffitt Cancer Center & Research Institute)
Catharine Wang, PhD, MSc (Boston University School of Public Health)
Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's Contact Form. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.